RyboDyn, Inc., based in San Diego, CA, is a biotechnology company pioneering the development of first-in-class immunotherapies targeting the dark genome. By leveraging RyboCypher™, a proprietary sequencing method and advanced bioinformatics platform, RyboDyn is uncovering and validating previously unknown proteins and disease-specific targets. With its scalable, in-house platform for lead discovery and optimization and proprietary IP licensed from Oregon Health & Science University, RyboDyn is driving a unique 'targets-to-assets' approach to therapeutic development.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/09/25 | $4,000,000 | Pre-Seed |
Genedant Capital SeaX Ventures | undisclosed |
